Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Cancer Cell. 2016 Mar 14;29(3):245-246. doi: 10.1016/j.ccell.2016.02.014.
The HIV1 protease inhibitor nelfinavir is being investigated as a cancer therapeutic. In this issue of Cancer Cell, Smith et al. (2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors.
HIV1 蛋白酶抑制剂奈非那韦正在被研究作为一种癌症治疗方法。在本期《癌细胞》杂志上，Smith 等人（2016 年）报告称，奈非那韦抑制了黑色素瘤细胞中 MAPK 通路抑制诱导的 MITF 表达，并使具有 NRAS 或 BRAF 加 NRAS 突变的黑色素瘤细胞对 MEK 抑制剂敏感。
